JNJørn Dalsgaard Nielsen

Jørn Dalsgaard Nielsen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jørn Dalsgaard Nielsen has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Endovascular treatment of iliofemoral venous thrombosis

    by Lærke Urbak, Jørn Dalsgaard Nielsen, Mikkel Taudorf, Søren Thorup Heerwagen, Nikolaj Eldrup, Niels Bækgaard

    Endovenous procedures have been shown to offer an effective treatment for Iliofemoral deep venous thrombosis with a clinically relevant reduction in postthrombotic syndrome (PTS) compared to anticoagulation alone. Catheter-based thrombolysis reduces the risk of PTS but has been shown to cause periprocedural bleeding in about 3%. This review finds that mechanical thrombectomy has emerged as an ideal technique, with thrombus extraction without bleeding and a significant reduction in PTS at 12 months. A large randomised controlled trial including this technique versus anticoagulation is ongoing.

  • Open Access

    Discontinuation of warfarin prior to elective invasive procedures

    by Jørn Dalsgaard Nielsen, Thomas Steffen Hermann

    INTRODUCTION. Patients on warfarin are normally required to interrupt treatment for a fixed number of days prior to an invasive procedure. This study aimed to investigate the potential influence of the warfarin maintenance dose and the initial international normalised ratio (INR) level on the duration of the break required to achieve the planned target INR. METHODS. A total of 120 patients on self-managed warfarin treatment measured INR once daily for five days before the intervention and were guided by the anticoagulation clinic on when to discontinue warfarin. Depending on the bleeding risk of the planned intervention, the target INR on the day of the intervention was ≤ 1.4, ≤ 2.5 or ≤ 3.0. RESULTS. From day 1 to day 5 after interruption of warfarin, the INR ratio (INRdayX/INRday0) decreased exponentially, with wide interpatient variation in the rate of decrease. Patients with a maintenance warfarin dose < 25 mg/week decreased significantly less in INR during the first day after stopping warfarin than patients who received a higher maintenance dose (9% vs 15%; p < 0.04). The INR half-life after day 1 was 113 hours for patients receiving < 25 mg/week and 101 hours for patients receiving ≥ 25 mg/week. CONCLUSIONS. The duration of pre-interventional discontinuation of warfarin can be individualised by knowing the maintenance dose, baseline INR and target INR for the planned procedure. FUNDING. None. TRIAL REGISTRATION. Quality assessment study approved by the legal department of the Capital Region of Denmark. Approval number: p-2024-15914.

  • Open Access

    Control of warfarin treatment in patients with antiphospholipid syndrome and falsely high INR at point-of-care-testing

    by Jørn Dalsgaard Nielsen, Thomas Steffen Hermann, Konstantinos Dimopoulos, Anne Storgaard Nørskov


  • Open Access

    Deep vein thrombosis in the upper extremities focusing on Paget-Schrötter syndrome

    by Jørn Dalsgaard Nielsen, Thomas Steffen Hermann

    Among the three main forms of upper extremity deep vein thrombosis (UE-DVT), catheter-related UE-DVT has the highest incidence, cancer-associated UE-DVT the highest mortality, and primary UE-DVT (Paget-Schrötter syndrome) the most varied treatment proposals. This review finds that nticoagulant treatment (AC) for 3-6 months leads to symptom freedom or mild postthrombotic syndrome in most patients. Still, several studies show better results after surgical treatment if performed < 6 weeks after symptom onset. A randomized study of AC alone versus AC + surgery < 6 weeks in patients with persistent symptoms is warranted.

  • Graduated elastic compression stockings in the prevention of post-thrombotic syndrome: A systematic review and meta-analysis

    by Jørn Dalsgaard Nielsen, Thomas Steffen Hermann, Pernille Cecilie Ammundsen Fredskilde

    Background: The effect of graduated elastic compression stockings (ECS) in the prevention of post-thrombotic syndrome (PTS) has been questioned since a large randomized trial found no prophylactic effect of ECS. Objective: To assess the effect of the wearing time of ECS on the incidence of post-thrombotic syndrome (PTS) after proximal deep venous thrombosis, we performed a meta-analysis of the incidence of PTS across randomized and observational studies. Method: PubMed, Embase and Cochrane databases were searched until 12 June 2023 for studies on the effect of ECS on PTS. References of eligible studies were also screened in order to identify other potential studies that might have been missed during the search. Results: Four studies comprising a total of 1467 patients met our inclusion criteria for early initiation and consistent use of ECS in patients with acute proximal DVT. ECS significantly reduced the incidence of mild-moderate PTS (OR: 0.48; 95% CI: 0.36–0.63) as well as severe PTS (OR: 0.44; 95% CI: 0.28–0.58).


    • 1 October 2018
      • Vol. 180

    [Recurrence of venous thromboembolism].

    by Jørn Dalsgaard Nielsen, Erik Lerkevang Grove, Torben Bjerregaard Larsen, Anette Asbjerg Højen

    Recurrence of venous thromboembolism (VTE) is seen in approximately one third of the patients after discontinuation of therapy with anticoagulants. The duration of treatment seems to be of minor importance, as several studies have shown the same recurrence rate over years after treatment for three months and up to 24 months. In patients with reversible risk factors, three months of treatment seems to be sufficient. Treatment duration should be determined by physicians with special expertise in risk factors for VTE recurrence and bleeding complications.

    • 5 September 2016
      • Vol. 178  (36)

    [Thromboprophylaxis in medical patients].

    by Jørn Dalsgaard Nielsen

    • 29 February 2016
      • Vol. 178  (9) , V12150952

    [Perioperative heparin bridging is rarely indicated].

    by Jørn Dalsgaard Nielsen, Anna-Marie Bloch Münster, Steen Elkjær Husted

    Meta-analyses of cohort studies and a recent randomized, placebo-controlled study have shown that perioperative bridging of warfarin therapy with therapeutic doses of heparin results in a multi-fold increase in major bleeding but no reduction in the incidence of thromboembolism. It is time to reconsider heparin bridging: When is heparin bridging superfluous? When is prophylactic dosage indicated? And when is it safe to use therapeutic dosing?

  • The incidence of pulmonary embolism during deep vein thrombosis

    by J D Nielsen

    Among life-threatening cardiovascular diseases, pulmonary embolism (PE) is the third most common after myocardial infarction and stroke. PE is a manifestation of venous thromboembolism (VTE). PE shares risk factors with deep vein thrombosis (DVT) and is regarded as a consequence of DVT rather than a separate clinical entity. Risk factors for VTE include major surgery, major trauma, high age, myocardial infarction, chronic heart failure, prolonged immobility, malignancy, thrombophilia and prior VTE. It is, however, important to recognize that these factors are not equally important and not equally common in patients with PE and DVT, respectively. Compared with DVT, PE is more often associated with major surgery, major trauma, high age, myocardial infarction and chronic heart failure, whereas malignancy and thrombophilia primarily are clinical predictors of DVT. In patients with prior VTE the initial clinical manifestation strongly predicts the manifestation of recurrent episodes, i.e. patients with previous PE are more likely to develop recurrent PE than DVT while patients with DVT predominantly are at risk of recurrent DVT.


  • Open Access

    Application of basic and composite thrombelastography parameters in monitoring of the antithrombotic effect of the low molecular weight heparin dalteparin: an in vivo study

    by Ramin Artang, Niels J Frandsen, Jørn D Nielsen

    Low molecular weight heparin (LMWH) is in vast usage for treatment of thromboembolic diseases such as deep venous thrombosis and acute coronary syndromes. There are certain clinical situations where a quick point of care testing of the effect of LMWH would be useful. At this point there are no point of care devices available in the market for monitoring the effect of LMWH. Thrombelastography (TEG) evaluates the viscoelastic properties of blood during coagulation. The clinical application of TEG in monitoring LMWH treatment is not yet well defined. The purpose of this in vivo study was to systematically evaluate the most suitable TEG parameters for evaluation of the antithrombotic effect of LMWH. We furthermore evaluated for the first time the usefulness of the composite TEG parameter the Thrombodynamic Ratio (TDR) in monitoring LMWH treatment.